Maci is a Cell Therapy owned by Vericel, and is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing.

Maci are patient’s own cartilage cells, which are implanted into the cartilage defect in the knee. The cells are used to fill in the space where the cartilage has been damaged, thereby regenerating the damaged areas and helping to resolve the patient’s symptoms such as pain and problems moving the knee.

The revenue for Maci is expected to reach a total of $3.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Maci NPV Report.

Maci is originated and owned by Vericel.

Maci Overview

Maci is a tissue engineered product used to repair cartilage defects at the ends of the bones of the knee joint. It is formulated as implant for the route of intraarticular route of administration. It is indicated for the repair of symptomatic, full-thickness cartilage defects of the knee (grade III and IV of the Modified Outerbridge Scale) of 3-20 cm2 in skeletally mature adult patients.

Maci is under development for the treatment of cartilage defects of the knee in pediatrics.

Vericel Overview

Vericel develops and markets advanced cell therapies for sports medicine and severe burn care domain. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. It also holds an exclusive license for NexoBrid in North America for the treatment of severe thermal burns. Vericel has manufacturing facility in Cambridge, Massachusetts and sells its products to sports medicine orthopedic surgeons and specialized burn centers through cell therapy specialists in the US. Vericel is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$156.2 million for the fiscal year ended December 2021 (FY2021), an increase of 25.8% over FY2020. The operating loss of the company was US$7.9 million in FY2021, compared to an operating profit of US$2.4 million in FY2020. The net loss of the company was US$7.5 million in FY2021, compared to a net profit of US$2.9 million in FY2020. The company reported revenues of US$38.6 million for the third quarter ended September 2022, an increase of 4.1% over the previous quarter.

Quick View – Maci

Report Segments
  • Innovator (NME)
Drug Name
  • Maci
Administration Pathway
  • Intraarticular
Therapeutic Areas
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.